Jeremy Pantin

907 total citations
48 papers, 350 citations indexed

About

Jeremy Pantin is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Jeremy Pantin has authored 48 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 21 papers in Oncology and 14 papers in Genetics. Recurrent topics in Jeremy Pantin's work include CAR-T cell therapy research (16 papers), Hematopoietic Stem Cell Transplantation (15 papers) and Acute Myeloid Leukemia Research (8 papers). Jeremy Pantin is often cited by papers focused on CAR-T cell therapy research (16 papers), Hematopoietic Stem Cell Transplantation (15 papers) and Acute Myeloid Leukemia Research (8 papers). Jeremy Pantin collaborates with scholars based in United States, Brazil and Georgia. Jeremy Pantin's co-authors include Richard Childs, Phillip Scheinberg, Susan F. Leitman, Karen Quillen, Harvey G. Klein, Harvey J. Alter, Lisa Cook, Jennifer A. Daniel‐Johnson, Minoo Battiwalla and Xin Tian and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Transplantation.

In The Last Decade

Jeremy Pantin

40 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeremy Pantin United States	11	195	101	77	66	53	48	350
Pawinee Kupatawintu Thailand	10	178 0.9×	99 1.0×	22 0.3×	70 1.1×	29 0.5×	34	307
Jeffrey Gryn United States	11	231 1.2×	158 1.6×	28 0.4×	95 1.4×	119 2.2×	14	392
Hai Bai China	8	245 1.3×	101 1.0×	112 1.5×	68 1.0×	61 1.2×	39	385
Peter Rintels United States	9	174 0.9×	194 1.9×	11 0.1×	57 0.9×	55 1.0×	16	335
Jong‐Mi Lee South Korea	9	104 0.5×	77 0.8×	44 0.6×	32 0.5×	55 1.0×	30	246
Annika K. Hult Sweden	11	225 1.2×	43 0.4×	20 0.3×	98 1.5×	104 2.0×	31	388
Carole Saison France	9	161 0.8×	43 0.4×	77 1.0×	100 1.5×	106 2.0×	16	406
V.A.J.M. Kunst Netherlands	9	275 1.4×	46 0.5×	23 0.3×	67 1.0×	10 0.2×	14	371
Masumi Fujishima Japan	12	76 0.4×	173 1.7×	69 0.9×	39 0.6×	50 0.9×	26	361
Qiaochuan Li China	10	129 0.7×	49 0.5×	48 0.6×	53 0.8×	110 2.1×	32	296

Countries citing papers authored by Jeremy Pantin

Since Specialization

Citations

This map shows the geographic impact of Jeremy Pantin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy Pantin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy Pantin more than expected).

Fields of papers citing papers by Jeremy Pantin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy Pantin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy Pantin. The network helps show where Jeremy Pantin may publish in the future.

Co-authorship network of co-authors of Jeremy Pantin

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy Pantin. A scholar is included among the top collaborators of Jeremy Pantin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy Pantin. Jeremy Pantin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Koreth, John, Jeremy Pantin, Shukaib Arslan, et al.. (2025). Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.. Blood. 146(Supplement 1). 274–274.

Majhail, Navneet S., Minoo Battiwalla, Aravind Ramakrishnan, et al.. (2025). Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring. JCO Oncology Practice. 21(11). 1601–1608. 1 indexed citations

Alsina, Melissa, Binod Dhakal, Jeremy Pantin, Carol Ann Huff, & Murali Janakiram. (2025). Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable. Future Oncology. 21(10). 1137–1144. 1 indexed citations

Martin, Casey, Betsy Blunk, Sarah T. Garber, et al.. (2025). Remote Patient Monitoring for 15 Vs. 30 Days in Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System. Transplantation and Cellular Therapy. 31(2). S223–S224.

Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2024). Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network. Blood Advances. 9(2). 429–435. 4 indexed citations

Shah, Bijal, Jeremy Pantin, Karamjeet Sandhu, et al.. (2024). Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel). Blood. 144(Supplement 1). 4837–4837.

Srour, Samer A., Jeremy Pantin, Sagar S. Patel, et al.. (2024). AML-521 Treatment of Acute Myeloid Leukemia With Orca-T. Clinical Lymphoma Myeloma & Leukemia. 24. S317–S317. 1 indexed citations

Martin, Casey, Betsy Blunk, Aravind Ramakrishnan, et al.. (2024). Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System. Blood. 144(Supplement 1). 2300–2300. 1 indexed citations

Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2023). Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non-Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network. Transplantation and Cellular Therapy. 29(2). S55–S55. 2 indexed citations

10.

Oliai, Caspian, Jeremy Pantin, Lori Muffly, et al.. (2023). Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies. Blood. 142(Supplement 1). 230–230. 2 indexed citations

11.

Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2023). Outcomes for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network. Transplantation and Cellular Therapy. 29(2). S211–S211.

12.

Patel, Sagar S., Edmund K. Waller, Jeremy Pantin, et al.. (2023). High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T. Blood. 142(Supplement 1). 2230–2230. 2 indexed citations

13.

Matthews, Rachel, David S. Bell, Carlos Bachier, et al.. (2021). The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy. Journal of Oncology Pharmacy Practice. 29(1). 45–51.

14.

Emadi, Ashkan, Vu H. Duong, Jeremy Pantin, et al.. (2018). Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial. Blood. 132(Supplement 1). 332–332. 10 indexed citations

15.

Purev, Enkhtsetseg, Xin Tian, Georg Aue, et al.. (2017). Allogeneic transplantation using CD34⁺ selected peripheral blood progenitor cells combined with non‐mobilized donor T cells for refractory severe aplastic anaemia. British Journal of Haematology. 176(6). 950–960. 6 indexed citations

16.

Pantin, Jeremy, Enkhtsetseg Purev, Xin Tian, et al.. (2016). Effect of high-dose plerixafor on CD34 ⁺ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 102(3). 600–609. 44 indexed citations

17.

Pantin, Jeremy, Lisa Cook, Roger Kurlander, et al.. (2015). Conditioning with rabbit versus horse ATG dramatically alters clinical outcomes in identical twins with severe aplastic anemia transplanted with the same allogeneic donor. Journal of Hematology & Oncology. 8(1). 78–78. 15 indexed citations

18.

Kovacsovics, Tibor, Alice S. Mims, Mohamed E. Salama, et al.. (2015). O-desulfated heparin and chemotherapy for the treatment of AML.. Journal of Clinical Oncology. 33(15_suppl). 7053–7053. 3 indexed citations

19.

Pantin, Jeremy, Xin Tian, Roger Kurlander, et al.. (2013). Rapid donor T‐cell engraftment increases the risk of chronic graft‐versus‐host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes. American Journal of Hematology. 88(10). 874–882. 4 indexed citations

20.

Gordeuk, Victor R., Gladys Onojobi, Ishmael Kasvosve, et al.. (2008). Ferroportin q248h, Dietary Iron, and Serum Ferritin in Community African‐Americans With Low to High Alcohol Consumption. Alcoholism Clinical and Experimental Research. 32(11). 1947–1953. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact